Holen Sie sich die Stockscreener-App
3.46
0.58%
0.02
Handel nachbörslich:
3.41
-0.05
-1.45%
Schlusskurs vom Vortag:
$3.44
Offen:
$3.44
24-Stunden-Volumen:
654.63K
Relative Volume:
0.48
Marktkapitalisierung:
$267.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-78.15M
KGV:
-4.0359
EPS:
-0.8573
Netto-Cashflow:
$-68.89M
1W Leistung:
+1.47%
1M Leistung:
-12.85%
6M Leistung:
+57.99%
1J Leistung:
+0.58%
1-Tages-Spanne:
$3.40
$3.515
1-Wochen-Bereich:
$3.255
$3.56
52-Wochen-Spanne:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.46 | 275.56M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
484.03 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
772.11 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.30 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
197.81 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
329.80 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Guggenheim | Buy |
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
Eledon Pharmaceuticals Inc (ELDN) Cash Flow - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELDN - TradingView
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - Sahm
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eledon’s BESTOW Trial Completion: What Tegoprubart Could Mean for Transplant Investing - TipRanks
ELDN Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw - Investing.com Canada
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Sahm
Eledon Pharmaceuticals (ELDN) Edges Higher as Stock Approaches Key Resistance at $4.15Leading Diagonal - dars.gov.et
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000 Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Price to earnings forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Price to earnings forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Price to sales forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - Sahm
Eledon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ELDN) - TradingView
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
ELDN Forecast — Price Target — Prediction for 2027 - TradingView
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - BioSpace
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Nigeria
Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN) - The Globe and Mail
NEWSLETTER: Drug to prevent organ rejection after kidney transplant tops standard treatment in trial - Reuters
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus - Sahm
Eledon Pharmaceuticals Amends Certificate of Incorporation – Key Changes Filed in 8-K SEC Report - Minichart
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney TransplantationSlideshow (NASDAQ:ELDN) 2026-06-22 - Seeking Alpha
Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote - TipRanks
Leerink raises Eledon Pharmaceuticals price target on trial data - Investing.com
Eledon (NASDAQ: ELDN) holders approve share increase and board slate - Stock Titan
Eledon reports Phase 2 BESTOW kidney transplant data - grafa.com
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation - marketscreener.com
Eledon Pharmaceuticals (ELDN) Presents Promising Phase 2 BESTOW Study Data - GuruFocus
Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data - Investing.com South Africa
Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus - marketscreener.com
Eledon reports kidney function benefit for tegoprubart at 18 months - Investing.com
Eledon reports kidney function benefit for tegoprubart at 18 months By Investing.com - Investing.com South Africa
Eledon Presents Long-Term Extension Phase 2 BESTOW Results - GlobeNewswire
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eledon Pharmaceuticals Inc-Aktie (ELDN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hillson Jan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Kirk Allan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Katkin Keith | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
8,575 |
0 |
8,575 |
| Lee June | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Robinson James A. Jr. | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
1.19%
1.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):